Omni Bio Pharm Inc (OMBP) 0.0300 $OMBP
World Gouty Arthritis (Gout) Pipeline Review, H2 2015
M2 - Wed Jan 06, 8:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/2jx4t4/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Report Coverage - Gouty Arthritis (Gout) Overview - Therapeutics Development - Pipeline Products for Gouty Arthritis (Gout) - Overview - Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis - Gouty Arthritis (Gout) - Therapeutics under Development by Companies - Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes - Gouty Arthritis (Gout) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Gouty Arthritis (Gout) - Products under Development by Companies - Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes - Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development Companies Mentioned - AstraZeneca Plc - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - LG Life Science LTD. - Monosol Rx, LLC - Nimbus Therapeutics, LLC - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Limited - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/2j..._arthritis
AZN: 28.65 (+0.23), CBAY: 1.77 (+0.02), PLXP: ()
Gouty Arthritis (Gout) Pipeline Review, H1 2015 - 20 Companies & 37 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zcbqd/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/7z..._arthritis
AZN: 28.65 (+0.23), CBAY: 1.77 (+0.02)
Global Myocardial Infarction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sc3q/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alligator Bioscience AB - AstraZeneca PLC - Athersys, Inc. - Bayer AG - CellProthera - Compugen Ltd. - CSL Limited - FibroGen, Inc. - Fina Biotech - Genextra S.p.a. - GlaxoSmithKline plc - GliaMed, Inc. - Hadasit Medical Research Services & Development Ltd - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - LegoChem Biosciences, Inc - LG Life Sciences, Ltd. - Ligand Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Omni Bio Pharmaceutical Inc. - Pluristem Therapeutics Inc. - Polyphor Ltd. - Quantum Genomics SA - Recardio GmbH - Remedy Pharmaceuticals, Inc. - Targazyme, Inc. - Vicore Pharma AB - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/m6sc3q/myocardial
PSTI: 1.26 (-0.02), MRK: 56.47 (+0.33), AZN: 28.65 (+0.23), CGEN: 6.58 (-0.02), FGEN: 15.67 (-0.28), GSK: 41.58 (+0.09), ATHX: 2.16 (-0.03)
Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles
M2 - Mon Apr 27, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjmb6v/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Adienne Pharma & Biotech - Alder Biopharmaceuticals Inc. - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Biogen Idec Inc. - Dr. Falk Pharma GmbH - Enlivex Therapeutics Ltd - Escape Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - Lycera Corp. - Mesoblast Limited - Millennium Pharmaceuticals, Inc. - MSM Protein Technologies, Inc. - Neopharm Ltd. - NeoStem, Inc. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmacyclics, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Targazyme, Inc. - Therapix Biosciences Ltd - Tobira Therapeutics, Inc. - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/bj...ersus_host
BIIB: 236.08 (-1.31), PCYC: 261.25 (+1.70), PSTI: 1.26 (-0.02), NBS: 2.25 (-0.09), ALDR: 26.40 (-0.59), BLCM: 12.90 (+0.08), ALXN: 123.14 (-0.82), ATHX: 2.16 (-0.03), TBRA: 12.00 (-0.19), NVS: 79.21 (+0.54)
Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions
Marketwired - Wed Nov 19, 3:20PM CST
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"
, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the presentation of Phase 1/2 clinical data for plasma-derived alpha-1 antitrypsin ("p-AAT" , demonstrating its ability to inhibit the inflammatory response in patients with acute ST-elevation myocardial infarction ("STEMI" , the most severe type of heart attack. The data were presented yesterday in a poster at the American Heart Association Scientific Sessions 2014, in Chicago. Importantly, these latest clinical findings further highlight the potential value of Omni Bio's first-in-class recombinant AAT candidate, AAT-Fc.
Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic
Marketwired - Wed Nov 19, 3:18PM CST
Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) ("Omni Bio" , an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today its manufacturing partners, Patheon and Sigma-Aldrich Fine Chemicals (SAFC), have successfully identified several high-expression cell lines able to produce Omni Bio's novel recombinant alpha-1 antitrypsin molecule (AAT-Fc) in large enough quantities to be considered commercially viable. This is a highly significant de-risking milestone that enables Omni Bio to move toward IND-enabling toxicology studies with the first and only pharmaceutically feasible recombinant AAT candidate currently in development.
World Gouty Arthritis (Gout) Pipeline Review, H2 2015
M2 - Wed Jan 06, 8:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/2jx4t4/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Report Coverage - Gouty Arthritis (Gout) Overview - Therapeutics Development - Pipeline Products for Gouty Arthritis (Gout) - Overview - Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis - Gouty Arthritis (Gout) - Therapeutics under Development by Companies - Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes - Gouty Arthritis (Gout) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Gouty Arthritis (Gout) - Products under Development by Companies - Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes - Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development Companies Mentioned - AstraZeneca Plc - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - LG Life Science LTD. - Monosol Rx, LLC - Nimbus Therapeutics, LLC - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Limited - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/2j..._arthritis
AZN: 28.65 (+0.23), CBAY: 1.77 (+0.02), PLXP: ()
Gouty Arthritis (Gout) Pipeline Review, H1 2015 - 20 Companies & 37 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zcbqd/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/7z..._arthritis
AZN: 28.65 (+0.23), CBAY: 1.77 (+0.02)
Global Myocardial Infarction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sc3q/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alligator Bioscience AB - AstraZeneca PLC - Athersys, Inc. - Bayer AG - CellProthera - Compugen Ltd. - CSL Limited - FibroGen, Inc. - Fina Biotech - Genextra S.p.a. - GlaxoSmithKline plc - GliaMed, Inc. - Hadasit Medical Research Services & Development Ltd - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - LegoChem Biosciences, Inc - LG Life Sciences, Ltd. - Ligand Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Omni Bio Pharmaceutical Inc. - Pluristem Therapeutics Inc. - Polyphor Ltd. - Quantum Genomics SA - Recardio GmbH - Remedy Pharmaceuticals, Inc. - Targazyme, Inc. - Vicore Pharma AB - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/m6sc3q/myocardial
PSTI: 1.26 (-0.02), MRK: 56.47 (+0.33), AZN: 28.65 (+0.23), CGEN: 6.58 (-0.02), FGEN: 15.67 (-0.28), GSK: 41.58 (+0.09), ATHX: 2.16 (-0.03)
Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles
M2 - Mon Apr 27, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjmb6v/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Adienne Pharma & Biotech - Alder Biopharmaceuticals Inc. - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Biogen Idec Inc. - Dr. Falk Pharma GmbH - Enlivex Therapeutics Ltd - Escape Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - Lycera Corp. - Mesoblast Limited - Millennium Pharmaceuticals, Inc. - MSM Protein Technologies, Inc. - Neopharm Ltd. - NeoStem, Inc. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmacyclics, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Targazyme, Inc. - Therapix Biosciences Ltd - Tobira Therapeutics, Inc. - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/bj...ersus_host
BIIB: 236.08 (-1.31), PCYC: 261.25 (+1.70), PSTI: 1.26 (-0.02), NBS: 2.25 (-0.09), ALDR: 26.40 (-0.59), BLCM: 12.90 (+0.08), ALXN: 123.14 (-0.82), ATHX: 2.16 (-0.03), TBRA: 12.00 (-0.19), NVS: 79.21 (+0.54)
Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions
Marketwired - Wed Nov 19, 3:20PM CST
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"
, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the presentation of Phase 1/2 clinical data for plasma-derived alpha-1 antitrypsin ("p-AAT" , demonstrating its ability to inhibit the inflammatory response in patients with acute ST-elevation myocardial infarction ("STEMI" , the most severe type of heart attack. The data were presented yesterday in a poster at the American Heart Association Scientific Sessions 2014, in Chicago. Importantly, these latest clinical findings further highlight the potential value of Omni Bio's first-in-class recombinant AAT candidate, AAT-Fc. Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic
Marketwired - Wed Nov 19, 3:18PM CST
Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) ("Omni Bio"
, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today its manufacturing partners, Patheon and Sigma-Aldrich Fine Chemicals (SAFC), have successfully identified several high-expression cell lines able to produce Omni Bio's novel recombinant alpha-1 antitrypsin molecule (AAT-Fc) in large enough quantities to be considered commercially viable. This is a highly significant de-risking milestone that enables Omni Bio to move toward IND-enabling toxicology studies with the first and only pharmaceutically feasible recombinant AAT candidate currently in development. 
